Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

2015 ◽  
Vol 82 (6) ◽  
pp. 885-891 ◽  
Author(s):  
Mehri Jamilian ◽  
Maryamalsadat Razavi ◽  
Zohreh Fakhrie Kashan ◽  
Yasser Ghandi ◽  
Tayebeh Bagherian ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Metabolic Response ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Selenium Supplementation ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

2008 ◽  
Vol 89 (5) ◽  
pp. 1221-1228 ◽  
Author(s):  
Åsa Lindholm ◽  
Marie Bixo ◽  
Inger Björn ◽  
Pål Wölner-Hanssen ◽  
Mats Eliasson ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Weight Reduction ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo

Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

2015 ◽  
Vol 67 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Mehri Jamilian ◽  
Zatollah Asemi
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Cell Function ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Chromium Picolinate ◽  
Model Assessment ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Insulin Metabolism ◽  
Double Blind Placebo

Background: The aim of the present study was to evaluate the beneficial effects of chromium intake on markers of insulin metabolism and lipid profiles in women with polycystic ovary syndrome (PCOS). Methods: In a prospective, randomized, double-blind, placebo-controlled trial, 64 women with PCOS were randomized to receive 200 µg chromium picolinate supplements (n = 32) or placebo (n = 32) for 8 weeks. Fasting blood samples were obtained at baseline and 8 weeks after the intervention to quantify markers of insulin metabolism and lipid concentrations. Results: Chromium supplementation in women with PCOS resulted in significant decreases in serum insulin levels (-3.6 ± 7.4 vs. +3.6 ± 6.2 µIU/ml, p < 0.001), homeostasis model of assessment-insulin resistance (HOMA-IR; -0.8 ± 1.6 vs. +0.9 ± 1.5, p < 0.001), homeostatic model assessment-beta cell function (HOMA-B; -15.5 ± 32.3 vs. +13.6 ± 23.1, p < 0.001), and a significant increase in quantitative insulin sensitivity check index (QUICKI) score (+0.02 ± 0.03 vs. -0.008 ± 0.02, p = 0.001) compared with the placebo. In addition, a trend toward a significant effect of chromium supplementation on decreasing serum triglycerides (-12.4 ± 74.4 vs. +15.2 ± 32.4 mg/dl, p = 0.05), very low-density lipoprotein-cholesterol (-2.5 ± 14.9 vs. +3.0 ± 6.5 mg/dl, p = 0.05), and cholesterol concentrations (-8.6 ± 21.9 vs. +0.7 ± 22.4 mg/dl, p = 0.09) was seen. Conclusions: Eight weeks of chromium supplementation among PCOS women had favorable effects on markers of insulin metabolism.

Sign in / Sign up

Export Citation Format

Share Document